Despite the increased risk of developing cryptococcosis among patients using anti-TNF antagonists [41,42], a therapeutic option to evaluate in larger studies would be to target inhibition of TNF-α for the alleviation of the neurological symptoms associated with CM-IRIS, as suggested in two case reports [43,44]. Here, TNF is linked to cutaneous mastocytosis.